Showing 1682 results
-
Press release /ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1Well-controlled…
-
Press release /Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension demonstrated the efficacy and safety of continuous Kesimpta® (ofatumumab) treatment and in those switched from teriflunomide, with…
-
Featured News /
From January 21-24 2020, Novartis attended the World Economic Forum Annual Meeting in Davos, Switzerland.
-
Story /In Cameroon, seeking treatment for chronic diseases can be a long journey.
-
Statement /
-
Featured News /
We teamed up with Medikidz and the COPD Foundation to develop a creative way to explain COPD to children.
-
In The News /A guest blog post from Anthony Gitau, Country Head of Novartis Access and Familia Nawiri in Kenya.
-
Statement /
-
Ad hoc release /The U.S. Food and Drug Administration (FDA) has not raised any concerns related to the efficacy or safety of inclisiran. The complete response letter is due to unresolved facility inspection-related…